U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365410) titled 'Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study' on Nov. 26, 2025.
Brief Summary: This multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases. It aims to determine which approach is more effective and safer.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Non-small Cell Lung Cancer (NSCLC)
Brain Metastases
Furmonertinib
EGFR Mutation
Intervention:
DRUG: Furmonertinib
Oral admi...